Cheng et al. showed that inhibiting IRAK1 makes hepatocellular carcinoma cells sensitive to doxorubicin and Sorafenib by suppressing apoptotic cascade in vitro (23). This evidence concerns the gene IRAK1 and hepatocellular carcinoma.